Can non-viral gene therapies solve the safety problem holding back genetic medicine?
Viral vectors built gene therapy’s first era. Safety, redosing and manufacturing pressure are pushing non-viral platforms into the spotlight.
Features & Analysis
Features & Analysis
Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Features & Analysis
Is endometriosis diagnosis finally moving beyond surgery after years of missed symptoms?
Endometriosis testing is escaping the surgery-first era. Saliva, blood and imaging tools now face the harder test: clinical utility.
Features & Analysis
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
Features & Analysis
Why BrioHealth’s Brio4Kids trial could become a test case for pediatric LVAD innovation
BrioHealth Solutions has received United States Food and Drug Administration conditional approval to initiate the Brio4Kids Trial, a pediatric clinical evaluation of the BrioVAD System in children with advanced heart failure. The trial will proceed under the existing Investigational Device Exemption for the INNOVATE Trial, giving the medical device developer a defined pathway to test
Features & Analysis
Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
Bristol Myers Squibb and Pfizer have brought Eliquis, the oral anticoagulant apixaban, into a new direct access channel through Mark Cuban Cost Plus Drug Company, making the medicine available to cash-paying patients in the United States from April 27, 2026. The move places one of the country’s most widely prescribed branded blood thinners inside a
Features & Analysis
Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Features & Analysis
Can Teva Pharmaceutical Industries Ltd.’s Home Ground platform reshape schizophrenia support beyond medication?
Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.
Features & Analysis
Academic partnerships signal Propanc Biopharma, Inc. push into aging biology and tumor resistance science
Propanc Biopharma expands Spanish research alliances ahead of first human oncology trials. Discover what this means for PRP development and strategy.
Features & Analysis
Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.